The average price of medicines is reduced by 56%

The average price of medicines is reduced by 56%

Yangcheng Evening News reporter Chen Zeyun

On June 28, Shanghai Sunshine Pharmaceutical Purchasing Network issued the "Notice on Announcement of the Results of the National Centralized Procurement of Pharmaceuticals", which means that the results of the fifth batch of national centralized procurement of pharmaceuticals were officially announced

According to previously announced documents, the total amount of drugs involved in the fifth batch of national drug procurement on the provincial procurement platform in 2020 will be as high as 55 billion yuan.

What are the new changes in this collection compared to the previous ones? What are the major varieties of 61 drugs? What new changes will it bring to the common people and corporate market competition? A reporter from the Yangcheng Evening News sorted out the "most" of this collection for you

The biggest drop has drug prices plummeting 98%

The price of esomeprazole injection for the treatment of acute gastric ulcers has been reduced from 65 yuan per tube to about 4 yuan per tube, which can save 610 yuan per treatment cycle; the new-generation diabetes drug saxagliptin is reduced by 62%, and the monthly cost is reduced by 62%.

Among the 61 winning bidders, Qilu Pharmaceutical's rivaroxaban (10mg) achieved a 98% drop, the highest drop in this round of drugs

In this centralized procurement, there were also "a few cents" of medicines reappearing

The most "new" battlefield injections fight fiercely

This round of centralized procurement is the first centralized procurement with injections as the main force

Why is the competition for injections so fierce? Insiders pointed out that, unlike oral dosage forms, injections are mainly used in medical institutions

In the fifth batch of centralized drug procurement organized by countries, 11 products of 10 foreign pharmaceutical companies are planned to be selected, involving French Sanofi, American General Motors, German Fresenius, Israel Teva, etc.

The local pharmaceutical companies are also fiercely competing for the injection market

The most "harvest" pharmaceutical enterprises leading companies become large gatherings

The trend of gathering bid-winning enterprises to "leading enterprises" is becoming more and more obvious

Large pharmaceutical companies are also more decisive in bargaining prices.

However, while leading companies have drastically cut prices and won the bids, some pharmaceutical companies are still able to win bids with higher prices under the existing quotation framework

The most "thrilling" these companies step on the car

Participating countries' centralized procurement of drugs, whether oral or injectable, has a hard standard that must pass the drug consistency evaluation

On June 22, the State Food and Drug Administration announced that 9 varieties of metoprolol tartrate tablets and ceftriaxone sodium for injection were all newly reviewed companies.

【Edit: Li Ji】